Aynur Acibuca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aynur Acibuca has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Mustafa Kilickap
Department of Cardiology, Ankara University Faculty of Medicine, Ankara, Turkey
3 shared publications Mustafa Yilmaz
Department of Cardiology, Baskent University School of Medicine, Dr Turgut Noyan Practice and Research Center, Adana, Turkey
3 shared publications- Basar Candemir
Department of Cardiology Ankara University Ankara Turkey
2 shared publications - Cetin Erol
Department of Cardiology, Faculty of Medicine, Ankara University, Ankara, Türkiye
2 shared publications Demet Menekse Gerede
Department of Cardiology, Ankara University School of Medicine, Ankara, Turkey
2 shared publicationsDm Gerede
Department of Cardiology, Ankara University School of Medicine, Ankara, Turkey
2 shared publications
Latest Publications
- Open Access
- 21 May 2023
- Published by Sakarya Tip Dergisi in Sakarya Medical Journal
Pertuzumab-mediated Cardiotoxicity: A Single Center Study.
Pertuzumab-mediated Cardiotoxicity: A Single Center Study. Objective: Recent clinical trials have shown that adding pertuzumab to trastuzumab improved the cellular response to therapy and provides a survival benefit compared with trastuzumab alone. However, it has raised concerns about additive risk of cardiotoxicity. Real life data on pertuzumab-induced cardiotoxicity are limited. Materials and Methods: Patients a diagnosis of breast cancer who had been treated trastuzumab plus pertuzumab between January 2017 and June 2022 and had undergone regularly transthoracic echocardiography, as a part of control visits, in our medical center were included. We performed descriptive statistical analysis to evaluate the patients’ characteristics and therapies, which could increase the risk of cardiac adverse events. Cardiotoxicity was evaluated by serial left ventricular ejection fraction (LVEF) measuring by 2D echocardiography at baseline and every three months during pertuzumab therapy and was defined as a decrease in LVEF > 10% to below 55%. Results: There were 118 patients fulfilling the inclusion criteria. The median age of the population was 51 (41-60) years. The median duration of pertuzumab therapy was 15 (9–57) weeks. Pertuzumab therapy was discontinued in two patients because of an allergic reaction and in other two patients due to cardiotoxicity. The reduced LVEF did not recover to baseline values in either patient. Conclusion: The incidence of cardiotoxicity (1.69%) in the current study was no higher than expected for trastuzumab alone. Data from previous studies and the results of this study support that pertuzumab causes no increase in cardiotoxicity. Still, large clinical trials are needed to verify the cardiac safety of pertuzumab in a real-world setting.
- 21 May 2023
- Published by Sakarya Tip Dergisi in Sakarya Medical Journal
Open AccessPertuzumab-mediated Cardiotoxicity: A Single Center Study.
Pertuzumab-mediated Cardiotoxicity: A Single Center Study. Objective: Recent clinical trials have shown that adding pertuzumab to trastuzumab improved the cellular response to therapy and provides a survival benefit compared with trastuzumab alone. However, it has raised concerns about additive risk of cardiotoxicity. Real life data on pertuzumab-induced cardiotoxicity are limited. Materials and Methods: Patients a diagnosis of breast cancer who had been treated trastuzumab plus pertuzumab between January 2017 and June 2022 and had undergone regularly transthoracic echocardiography, as a part of control visits, in our medical center were included. We performed descriptive statistical analysis to evaluate the patients’ characteristics and therapies, which could increase the risk of cardiac adverse events. Cardiotoxicity was evaluated by serial left ventricular ejection fraction (LVEF) measuring by 2D echocardiography at baseline and every three months during pertuzumab therapy and was defined as a decrease in LVEF > 10% to below 55%. Results: There were 118 patients fulfilling the inclusion criteria. The median age of the population was 51 (41-60) years. The median duration of pertuzumab therapy was 15 (9–57) weeks. Pertuzumab therapy was discontinued in two patients because of an allergic reaction and in other two patients due to cardiotoxicity. The reduced LVEF did not recover to baseline values in either patient. Conclusion: The incidence of cardiotoxicity (1.69%) in the current study was no higher than expected for trastuzumab alone. Data from previous studies and the results of this study support that pertuzumab causes no increase in cardiotoxicity. Still, large clinical trials are needed to verify the cardiac safety of pertuzumab in a real-world setting.
- Open Access
- 13 December 2021
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 49 (12)
Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience
Objective: New anti-cancer drugs promise to increased survival benefits and reduce adverse events. Trastuzumab emtansine (T-DM1) is a novel anti-human epidermal growth factor receptor 2 agent that has shown minimal cardiotoxicity in clinical trials. However, data on real-life outcomes are required. Methods: A retrospective review of our center’s medical records was performed, including female patients aged ≥18 years with a diagnosis of metastatic breast cancer who were treated with T-DM1. Descriptive statistics were used to investigate clinical features that could increase the risk of cardiotoxicity. Cardiotoxicity was determined by comparing pre and post-T-DM1 echocardiogram results and was defined as a decrease in the left ventricular ejection fraction (LVEF) >10% to below 55%. Results: Data from 41 female patients with a mean age of 52 ± 11.5 years were evaluated. A significant LVEF decrease (from 59% to 33%) was observed in one patient during T-DM1 treatment. Further investigation showed that this decrease was due to underlying coronary artery disease, and LVEF recovered to the baseline value after coronary revascularization. Conclusion: T-DM1 seems to be safe in terms of cardiotoxicity. Real-life data with a larger sample size are still needed to confirm the cardiac safety of T-DM1.
- 13 December 2021
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 49 (12)
Open AccessCardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience
Objective: New anti-cancer drugs promise to increased survival benefits and reduce adverse events. Trastuzumab emtansine (T-DM1) is a novel anti-human epidermal growth factor receptor 2 agent that has shown minimal cardiotoxicity in clinical trials. However, data on real-life outcomes are required. Methods: A retrospective review of our center’s medical records was performed, including female patients aged ≥18 years with a diagnosis of metastatic breast cancer who were treated with T-DM1. Descriptive statistics were used to investigate clinical features that could increase the risk of cardiotoxicity. Cardiotoxicity was determined by comparing pre and post-T-DM1 echocardiogram results and was defined as a decrease in the left ventricular ejection fraction (LVEF) >10% to below 55%. Results: Data from 41 female patients with a mean age of 52 ± 11.5 years were evaluated. A significant LVEF decrease (from 59% to 33%) was observed in one patient during T-DM1 treatment. Further investigation showed that this decrease was due to underlying coronary artery disease, and LVEF recovered to the baseline value after coronary revascularization. Conclusion: T-DM1 seems to be safe in terms of cardiotoxicity. Real-life data with a larger sample size are still needed to confirm the cardiac safety of T-DM1.
- 31 August 2021
- Published by Clinics Cardive Publishing in CardioVascular Journal of Africa
- Vol. 32 (4) , 16-20
An epidemiological study to define the recent clinical characteristics and outcomes of infective endocarditis in southern Turkey
Introduction: The aim of this study was to characterise the recent features of patients with infective endocarditis (IE) at one referral centre in southern Turkey, in order to be able to identify the high-risk subgroup and revise preventative measures and management strategies. Methods: Medical records of patients 18 years and older, who had been diagnosed with IE according to the Duke criteria between January 2009 and October 2019, were retrospectively evaluated in a referral general hospital. Results: The total of 139 IE cases comprised 59.7% males and 40.3% females, with a mean age of 55 +/- 16 years. The most encountered symptom was fever (55.4%) and the mitral valve (54%) was the most frequently involved. The most common causative micro-organisms were coagulase-negative staphylococci (30.2%). The in-hospital mortality rate was 30.2%, with congestive heart failure, chronic renal disease and chronic dialysis found to be significantly associated with in-hospital mortality. Conclusion: The study results demonstrate the recent epidemiological features of IE in southern Turkey that are important for clinicians to manage diagnostic and therapeutic processes successfully. Older age, the predominance of staphylococci and higher surgery rates are consistent with the changing trends of IE in some parts the world.
- 31 August 2021
- Published by Clinics Cardive Publishing in CardioVascular Journal of Africa
- Vol. 32 (4) , 16-20
An epidemiological study to define the recent clinical characteristics and outcomes of infective endocarditis in southern Turkey
Introduction: The aim of this study was to characterise the recent features of patients with infective endocarditis (IE) at one referral centre in southern Turkey, in order to be able to identify the high-risk subgroup and revise preventative measures and management strategies. Methods: Medical records of patients 18 years and older, who had been diagnosed with IE according to the Duke criteria between January 2009 and October 2019, were retrospectively evaluated in a referral general hospital. Results: The total of 139 IE cases comprised 59.7% males and 40.3% females, with a mean age of 55 +/- 16 years. The most encountered symptom was fever (55.4%) and the mitral valve (54%) was the most frequently involved. The most common causative micro-organisms were coagulase-negative staphylococci (30.2%). The in-hospital mortality rate was 30.2%, with congestive heart failure, chronic renal disease and chronic dialysis found to be significantly associated with in-hospital mortality. Conclusion: The study results demonstrate the recent epidemiological features of IE in southern Turkey that are important for clinicians to manage diagnostic and therapeutic processes successfully. Older age, the predominance of staphylococci and higher surgery rates are consistent with the changing trends of IE in some parts the world.
- 26 July 2021
- Published by Academician Publishing
Onkolojik Aciller
Onkoloji alanındaki tüm dünyanın yakın takip ettiği bilimsel gelişmeler ışığında günümüzde artık sistemik kemoterapi gibi konvansiyonel tedaviler yerlerini büyük ölçüde immünoterapi, moleküler hedefli ilaçlar ve gen tedavilerine bırakmaya başlamıştır.Bu tedavi seçeneklerinin her biri ayrı ayrı vazgeçilmez önemde olup tedavi seçimleri ve sıralamaları bireyselleştirilmiş tedavi stratejilerisayesinde her hastaya özgü bir şekilde planlanmaktadır. Gerek bu tedavi modalitelerinin yan etkileri gerekse hastalığın doğal seyri gereği acil müdahele gerektiren durumların varlığı yadsınamaz. Dolayısıyla çağdaş tedavi modalitelerinin kullanım alanımıza girmesi Onkolojik Acillerin pratiğimizdeki yerini değiştirmemiştir ve Onkoloji pratiğinde hem hastalarımızın hem de bizlerin yönetiminde zaman zaman zorlandığımız bu konulara güncel yaklaşımları alanında uzman ve akademik vizyonu olan hocalarımızın katkılarıyla hazırladık.Emeği geçen hocalarıma teker teker davetimi kırmayıp verdikleri destek için teşekkür ediyorum. Ayrıca Onkoloji alanında yayımladığımız ve yayımlamayı planladığımız kitapların hazırlanmasında emeği geçen ve her an yanımızda olan başta Akademisyen Yayınevi sahibi Yasin DİLMEN olmak üzere tüm yayınevi çalışanlarına da teşekkür ederim.
- 26 July 2021
- Published by Academician Publishing
Onkolojik Aciller
Onkoloji alanındaki tüm dünyanın yakın takip ettiği bilimsel gelişmeler ışığında günümüzde artık sistemik kemoterapi gibi konvansiyonel tedaviler yerlerini büyük ölçüde immünoterapi, moleküler hedefli ilaçlar ve gen tedavilerine bırakmaya başlamıştır.Bu tedavi seçeneklerinin her biri ayrı ayrı vazgeçilmez önemde olup tedavi seçimleri ve sıralamaları bireyselleştirilmiş tedavi stratejilerisayesinde her hastaya özgü bir şekilde planlanmaktadır. Gerek bu tedavi modalitelerinin yan etkileri gerekse hastalığın doğal seyri gereği acil müdahele gerektiren durumların varlığı yadsınamaz. Dolayısıyla çağdaş tedavi modalitelerinin kullanım alanımıza girmesi Onkolojik Acillerin pratiğimizdeki yerini değiştirmemiştir ve Onkoloji pratiğinde hem hastalarımızın hem de bizlerin yönetiminde zaman zaman zorlandığımız bu konulara güncel yaklaşımları alanında uzman ve akademik vizyonu olan hocalarımızın katkılarıyla hazırladık.Emeği geçen hocalarıma teker teker davetimi kırmayıp verdikleri destek için teşekkür ediyorum. Ayrıca Onkoloji alanında yayımladığımız ve yayımlamayı planladığımız kitapların hazırlanmasında emeği geçen ve her an yanımızda olan başta Akademisyen Yayınevi sahibi Yasin DİLMEN olmak üzere tüm yayınevi çalışanlarına da teşekkür ederim.
- Open Access
- 1 January 2021
- Vol. 18 (7) , 591-594
A case of mediastinal mesenchymal tumor resembling hemopericardium
Mediastinal neoplasms are rare in the elderly, and clinical suspicion is the first and most important step of differential diagnosis. Mediastinal tumors can be misdiagnosed because their symptoms or signs can overlap with cardiovascular diseases, which have a higher prevalence among the older population. The diagnostic process should be managed with multimodality imaging and clinical judgement. Here, the case of a 74-year-old male patient, who presented with shortness of breath, is examined. A chest X-ray revealed an increased cardiothoracic ratio, and he was diagnosed with hemopericardium following an emergent chest computed tomography. In the echocardiography, it was suspected that a hyperechogenic area adjacent to the heart might be due to a mass, and further examinations confirmed a mediastinal neoplasm. A surgical biopsy was performed, and it was determined to be a mesenchymal tumor. To conclude, clinicians should keep in mind the possibility of paracardiac neoplasm in the elderly, as well as in other age groups, when encountering mediastinal widening so that the patient can be protected from unnecessary interventions such as pericardiocentesis.
- 1 January 2021
- Vol. 18 (7) , 591-594
Open AccessA case of mediastinal mesenchymal tumor resembling hemopericardium
Mediastinal neoplasms are rare in the elderly, and clinical suspicion is the first and most important step of differential diagnosis. Mediastinal tumors can be misdiagnosed because their symptoms or signs can overlap with cardiovascular diseases, which have a higher prevalence among the older population. The diagnostic process should be managed with multimodality imaging and clinical judgement. Here, the case of a 74-year-old male patient, who presented with shortness of breath, is examined. A chest X-ray revealed an increased cardiothoracic ratio, and he was diagnosed with hemopericardium following an emergent chest computed tomography. In the echocardiography, it was suspected that a hyperechogenic area adjacent to the heart might be due to a mass, and further examinations confirmed a mediastinal neoplasm. A surgical biopsy was performed, and it was determined to be a mesenchymal tumor. To conclude, clinicians should keep in mind the possibility of paracardiac neoplasm in the elderly, as well as in other age groups, when encountering mediastinal widening so that the patient can be protected from unnecessary interventions such as pericardiocentesis.
- 31 December 2020
- Published by Bayt Publications in The Turkish Journal of Geriatrics
- Vol. 23 (3) , 308-316
THE OUTCOMES OF USING FIXED-DOSE NOMOGRAM-GUIDED UNFRACTIONATED HEPARIN THERAPY IN ELDERLY PATIENTS IN COMPARISON WITH YOUNGER PATIENTS
- 31 December 2020
- Published by Bayt Publications in The Turkish Journal of Geriatrics
- Vol. 23 (3) , 308-316
THE OUTCOMES OF USING FIXED-DOSE NOMOGRAM-GUIDED UNFRACTIONATED HEPARIN THERAPY IN ELDERLY PATIENTS IN COMPARISON WITH YOUNGER PATIENTS
- Open Access
- 30 September 2020
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 45 (3) , 971-976
Blood pressure limits affecting carotid artery injury: a cross sectional study
Objective: Although it is well known that high blood pressure causes undesirable effects on carotid arteries, it is not clear as to which threshold value this effect starts. The aim of this study is to evaluate and determine this threshold. Materials and Methods: This cross-sectional study included a total of 308 individuals in the following groups; Group 1: individuals with systolic blood pressure (SBP) 86.5 mmHg with 79.3% sensitivity and 71.6% specificity. Carotid elasticity was seen to be affected by SBP>137.5 mmHg with 80.4% sensitivity and 73.1% specificity, and DBP>88.5 mmHg with 79.1% sensitivity and 73.8% specificity. Conclusion: Carotid distensibility and elasticity decreases with increasing blood pressure. In individuals with high-normal blood pressure, carotid damage may begin after a certain blood pressure value.
- 30 September 2020
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 45 (3) , 971-976
Open AccessBlood pressure limits affecting carotid artery injury: a cross sectional study
Objective: Although it is well known that high blood pressure causes undesirable effects on carotid arteries, it is not clear as to which threshold value this effect starts. The aim of this study is to evaluate and determine this threshold. Materials and Methods: This cross-sectional study included a total of 308 individuals in the following groups; Group 1: individuals with systolic blood pressure (SBP) 86.5 mmHg with 79.3% sensitivity and 71.6% specificity. Carotid elasticity was seen to be affected by SBP>137.5 mmHg with 80.4% sensitivity and 73.1% specificity, and DBP>88.5 mmHg with 79.1% sensitivity and 73.8% specificity. Conclusion: Carotid distensibility and elasticity decreases with increasing blood pressure. In individuals with high-normal blood pressure, carotid damage may begin after a certain blood pressure value.
- Open Access
- 1 January 2019
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 22 (3) , 152-154
The first case of cardiac amyloidosis presenting as right atrial mass
- 1 January 2019
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 22 (3) , 152-154
Open AccessThe first case of cardiac amyloidosis presenting as right atrial mass
- Open Access
- 1 January 2019
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 21 (5) , 287-+
Relapse of acute myeloid leukemia presenting with myocardial hypertrophy and constrictive pericardial physiology.
- 1 January 2019
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 21 (5) , 287-+
Open AccessRelapse of acute myeloid leukemia presenting with myocardial hypertrophy and constrictive pericardial physiology.
- Open Access
- 5 September 2018
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 46 (11) , 4518-4526
Serum neuron-specific enolase, a marker of neuronal injury, increases after catheter ablation of atrial fibrillation
Objective: Catheter ablation of atrial fibrillation (AF) can lead to thromboembolic complications, especially stroke. We measured the periprocedural serum neuron-specific enolase (NSE) level, which is a biomarker of neuronal injury, after ablation of AF. Methods: Forty-three patients with paroxysmal AF were prospectively enrolled before radiofrequency ablation. A neurological examination was performed before and after the procedure. The serum NSE level was determined before and at the end of the procedure and at 2, 24, and 48 h after the procedure. Results: No patients developed new neurological deficits. However, the median (interquartile range) NSE level increased after ablation from 6.7 (3.87) ng/mL at baseline to 11.48 (5.3) ng/mL at 24 h postoperatively. The NSE level exceed the upper reference limit of normal (17 ng/mL) in 14 patients (33%), and these patients were found to have a larger left atrium. Conclusions: Serum NSE increased in most of the patients undergoing ablation for AF, and it exceeded the normal limit in one-third of the patients. Although NSE is a biomarker of neuronal injury, the clinical importance of this increase after AF ablation and its relationship with the left atrial diameter should be evaluated in a longitudinal study.
- 5 September 2018
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 46 (11) , 4518-4526
Open AccessSerum neuron-specific enolase, a marker of neuronal injury, increases after catheter ablation of atrial fibrillation
Objective: Catheter ablation of atrial fibrillation (AF) can lead to thromboembolic complications, especially stroke. We measured the periprocedural serum neuron-specific enolase (NSE) level, which is a biomarker of neuronal injury, after ablation of AF. Methods: Forty-three patients with paroxysmal AF were prospectively enrolled before radiofrequency ablation. A neurological examination was performed before and after the procedure. The serum NSE level was determined before and at the end of the procedure and at 2, 24, and 48 h after the procedure. Results: No patients developed new neurological deficits. However, the median (interquartile range) NSE level increased after ablation from 6.7 (3.87) ng/mL at baseline to 11.48 (5.3) ng/mL at 24 h postoperatively. The NSE level exceed the upper reference limit of normal (17 ng/mL) in 14 patients (33%), and these patients were found to have a larger left atrium. Conclusions: Serum NSE increased in most of the patients undergoing ablation for AF, and it exceeded the normal limit in one-third of the patients. Although NSE is a biomarker of neuronal injury, the clinical importance of this increase after AF ablation and its relationship with the left atrial diameter should be evaluated in a longitudinal study.